Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial
Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the first premature infant has been enrolled and dosed in the Company´s Phase 2 clinical trial. This Phase 2 trial is a randomized, double blind, parallel group, dose escalation, placebo-controlled multicenter study to investigate the safety and tolerability of IBP-9414 administered in preterm infants. This is the first trial in the clinical development of IBP-9414 for the prevention of the often fatal disease necrotizing enterocolitis which affects premature infants. The multicenter trial is being conducted in a number of